NasdaqGS:REPL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Replimune Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: REPL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: REPL's weekly volatility has decreased from 14% to 9% over the past year.


Market Performance


7 Day Return

10.8%

REPL

4.4%

US Biotechs

0.6%

US Market


1 Year Return

138.8%

REPL

36.0%

US Biotechs

21.0%

US Market

Return vs Industry: REPL exceeded the US Biotechs industry which returned 33.3% over the past year.

Return vs Market: REPL exceeded the US Market which returned 22% over the past year.


Shareholder returns

REPLIndustryMarket
7 Day10.8%4.4%0.6%
30 Day7.5%5.6%4.2%
90 Day11.2%19.2%12.4%
1 Year138.8%138.8%38.2%36.0%23.7%21.0%
3 Yearn/a31.5%24.6%47.4%37.6%
5 Yearn/a48.8%37.4%131.6%105.9%

Long-Term Price Volatility Vs. Market

How volatile is Replimune Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Replimune Group undervalued compared to its fair value and its price relative to the market?

7.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate REPL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate REPL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: REPL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: REPL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate REPL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: REPL is overvalued based on its PB Ratio (7x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Replimune Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: REPL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: REPL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: REPL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if REPL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if REPL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: REPL is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Replimune Group performed over the past 5 years?

-46.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: REPL is currently unprofitable.

Growing Profit Margin: REPL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: REPL is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.

Accelerating Growth: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: REPL has a negative Return on Equity (-26.61%), as it is currently unprofitable.


Next Steps

Financial Health

How is Replimune Group's financial position?


Financial Position Analysis

Short Term Liabilities: REPL's short term assets ($252.4M) exceed its short term liabilities ($13.0M).

Long Term Liabilities: REPL's short term assets ($252.4M) exceed its long term liabilities ($39.9M).


Debt to Equity History and Analysis

Debt Level: REPL's debt to equity ratio (3.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if REPL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: REPL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: REPL has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 56.4% each year.


Next Steps

Dividend

What is Replimune Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate REPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate REPL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if REPL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if REPL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of REPL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Philip Astley-Sparke (49 yo)

1

Tenure

US$2,155,163

Compensation

Mr. Philip Astley-Sparke, FSA, has been the Chairman of uniQure N.V. since September 22, 2016 and its Director since June 15, 2015. He is a Co-founder of Replimune Group, Inc. and served as its Executive C...


CEO Compensation Analysis

Compensation vs Market: Philip's total compensation ($USD2.16M) is below average for companies of similar size in the US market ($USD3.85M).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Philip Astley-Sparke
CEO & Director1yrUS$2.16m2.84%
$ 59.5m
Robert Coffin
Founder6yrsUS$2.93m3.93%
$ 82.2m
Jean Franchi
Principal Accounting Officer1.08yrsUS$2.10mno data
Pamela Esposito
Chief Business Officer5.17yrsUS$1.23m0.38%
$ 8.0m
Colin Love
Chief Operating Officer5.25yrsUS$1.30m2.12%
$ 44.5m
Andrea Pirzkall
Chief Medical Officer0.50yrno data0.0022%
$ 45.7k

3.1yrs

Average Tenure

52yo

Average Age

Experienced Management: REPL's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Philip Astley-Sparke
CEO & Director1yrUS$2.16m2.84%
$ 59.5m
Robert Coffin
Founder6yrsUS$2.93m3.93%
$ 82.2m
Joseph Slattery
Independent Director3.25yrsUS$199.00k0.015%
$ 303.9k
Jason Rhodes
Independent Director5.33yrsUS$174.50k0%
$ 0
Hugo Slootweg
Independent Director6yrsUS$161.50k0%
$ 0
Otello Stampacchia
Independent Director5.67yrsUS$126.50k0%
$ 0
Hyam Levitsky
Independent Non-Executive Director2.67yrsUS$165.50k0%
$ 0
Paolo Pucci
Independent Director0.75yrno datano data
Tanya Lewis
Director1yrno datano data
Kapil Dhingra
Independent Director3.5yrsUS$179.00k0%
$ 0
Dieter Weinand
Independent Chairman of the Board0.75yrUS$169.00k0%
$ 0

3.5yrs

Average Tenure

55yo

Average Age

Experienced Board: REPL's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.


Top Shareholders

Company Information

Replimune Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Replimune Group, Inc.
  • Ticker: REPL
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.095b
  • Shares outstanding: 45.96m
  • Website: https://replimune.com

Number of Employees


Location

  • Replimune Group, Inc.
  • 500 Unicorn Park
  • 3rd Floor
  • Woburn
  • Massachusetts
  • 1801
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REPLNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2018
7R8DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2018

Biography

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intend...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/14 23:18
End of Day Share Price2021/01/14 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.